These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15487531)

  • 41. Myth: generic drugs are lower quality and less safe than brand-name drugs.
    Canadian Health Services Research Foundation
    J Health Serv Res Policy; 2007 Oct; 12(4):255-6. PubMed ID: 17925080
    [No Abstract]   [Full Text] [Related]  

  • 42. [Drugs for children--when temporary solutions become routine].
    Kalikstad B; Westergren T
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):930-2. PubMed ID: 16554887
    [No Abstract]   [Full Text] [Related]  

  • 43. [Users sceptical about generic drugs: an anthropological approach].
    Sarradon-Eck A; Blanc MA; Faure M
    Rev Epidemiol Sante Publique; 2007 Jun; 55(3):179-85. PubMed ID: 17459630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Generic drug substitution].
    Tamir O; Halkin H; Shemer J
    Harefuah; 2006 Sep; 145(9):691-5, 701. PubMed ID: 17078434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of alternative interventions on changes in generic dispensing rates.
    O'Malley AJ; Frank RG; Kaddis A; Rothenberg BM; McNeil BJ
    Health Serv Res; 2006 Oct; 41(5):1876-94. PubMed ID: 16987306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prescribing and dispensing generic drugs in the Mambéré-Kadéï health district of the Central African Republic].
    Mouala C; Abeye J; Somse P; Maritoux J; Goumba A
    Med Trop (Mars); 2008 Apr; 68(2):149-54. PubMed ID: 18630047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The Medical Products Agency and testosterone treatment. Act II].
    Lindholm J
    Ugeskr Laeger; 2005 May; 167(20):2200; author reply 2200. PubMed ID: 15987085
    [No Abstract]   [Full Text] [Related]  

  • 49. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
    Tilson L; Bennett K; Barry M
    Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [More or less generic substitution/ordination?].
    Waldorff S
    Ugeskr Laeger; 2012 Jan; 174(1-2):73. PubMed ID: 22334895
    [No Abstract]   [Full Text] [Related]  

  • 51. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
    Federman AD; Halm EA; Siu AL
    Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimizing information on drug exposure by collection of package code information in questionnaire surveys.
    Quinzler R; Schmitt SP; Szecsenyi J; Haefeli WE
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1024-30. PubMed ID: 17457950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The Medical Products Agency and testosterone treatment. The 3rd and the last act].
    Lindholm J
    Ugeskr Laeger; 2005 Aug; 167(33):3072-4. PubMed ID: 16109265
    [No Abstract]   [Full Text] [Related]  

  • 54. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies.
    Kersnik J; Peklar J
    J Clin Pharm Ther; 2006 Dec; 31(6):577-83. PubMed ID: 17176362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prescription of generic drugs in general practice. Results of a survey of general practitioners].
    Simmenroth-Nayda A; Hummers-Pradier E; Ledig T; Jansen R; Niebling W; Bjerre LM; Kochen MM; Himmel W
    Med Klin (Munich); 2006 Sep; 101(9):705-10. PubMed ID: 16977394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prescription by INN (International Non-Proprietary Name)].
    Elsen C; Nève J; Schetgen M
    J Pharm Belg; 2005; 60(3):77-83. PubMed ID: 16252508
    [No Abstract]   [Full Text] [Related]  

  • 57. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
    Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advertising and generic market entry.
    Königbauer I
    J Health Econ; 2007 Mar; 26(2):286-305. PubMed ID: 17011648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.